INS and diabetes mellitus: More recently, and in an even younger cohort (n = 112, aged 6–13.9 years), the 3-month pivotal trial of the tubeless OmniPodTM 5 automated insulin delivery system (Insulet Corporation, Acton, MA) has demonstrated a TIR that increased from 52.5% to 68% and SG that decreased from 183 to 160 mg/dL.38 All of these findings are of substantial import in youth with T1D, as TIR has been shown to associate with A1C39,40 and is evolving to become a standard predictor for diabetes complications risk.41–43